Lymphoma
Lymphoma
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
59
Clinical Trials
Lymphoma
Phase III
Enrolling
nct/study# NCT05605899 / KT-US-484-0136
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)
Learn More
Lymphoma
Phase I
Enrolling
nct/study# NCT04989803 / KT-US-499-0150-01
A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
Learn More
Lymphoma
Unspecified
Enrolling
nct/study# NCT05041309 / KT-US-982-5968
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Learn More
Lymphoma
N/A
Enrolling
nct/study# N/A / LONCASTUXIMAB
Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab: A Real World Multicenter Analysis
Learn More
Lymphoma
N/A
Enrolling
nct/study# N/A / LYMPHOPROLIFERATIVE
Outcomes of Patients with Lymphoproliferative Disorders
Learn More
Lymphoma
Phase II
Enrolling
nct/study# NCT04728893 / MK-1026-003
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.